|
February
21, 2007--Genentech
announced that a Roche-sponsored Phase III study evaluating two
different doses of Avastin (bevacizumab) in combination with
gemcitabine and cisplatin chemotherapy met the primary endpoint
of prolonging progression-free survival (PFS) in patients with
previously untreated, advanced non-squamous, non-small cell lung
cancer. Both doses of Avastin (15 mg/kg or 7.5 mg/kg every three
weeks) significantly improved PFS compared with chemotherapy
alone, as assessed by trial investigators. See Genentech
press release for additional study details.
|
